Becton Dickinson and Company (BDX) Shares are Down -0.07%

Becton Dickinson and Company (BDX) has risen sharply, recording gains of 0.1% in the past 4 weeks. However, the stock has corrected -0.07% in the past 1 week, providing a good buying opportunity on dips. Becton Dickinson and Company (BDX) : During the past 4 weeks, traders have been relatively bearish on Becton Dickinson and Company (BDX), hence the stock is down -0.28% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.04% relative to the S&P 500.

Becton, Dickinson and Company is up 5.77% in the last 3-month period. Year-to-Date the stock performance stands at 13.77%. The stock has recorded a 20-day Moving Average of 0.35% and the 50-Day Moving Average is 0.86%.


Becton Dickinson and Company (NYSE:BDX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $173.20 and $172.37 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $174.00. The buying momentum continued till the end and the stock did not give up its gains. It closed at $173.85, notching a gain of 0.09% for the day. The total traded volume was 713,720 . The stock had closed at $173.70 on the previous day.

Also, UBS maintains its rating on Becton Dickinson and Company (NYSE:BDX). The global brokerage major raises the current price target from $182 per share to $195 per share. Analysts at the UBS have a current rating of Buy on the shares. The rating by the firm was issued on August 5, 2016.

Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.